Summary
Nicorandil, a nicotinamide derivative, is an orally efficacious antianginal drug possessing a nitrate moiety in its chemical structure. This drug is an effective and welltolerated treatment for various types of angina pectoris. Its general efficacy is similar to that of nitrates, with several unique effects on the cardiovascular system. Nicorandil causes sustained dilation of both the arterial resistance and conductive vessels, thus markedly dilating the coronary artery and increasing coronary blood flow. In addition, nicorandil, unlike nitroglycerin or isosorbide dinitrate, possesses little hemodynamic effect on heart rate, blood pressure, or cardiac contractility with clinical doses yielding antianginal effects. The mechanism causing coronary vasodilation has not been completely clarified but appears to be associated partly with increases in c-GMP, as well as the hyperpolarization of the smooth muscle membrane.
Nicorandil, in single oral doses of 10–30 mg, has been shown to be effective in chronic stable angina, as assessed objectively by increases in exercise duration and/or the time to onset of ST-segment depression during treadmill exercise. In open studies and controlled efficacy evaluations, nicorandil in daily oral doses of 15–40 mg demonstrated significant effectiveness in the treatment of various types of angina pectoris. Headaches due to vasodilation may occur, and some side effects occurred in 5.1–34% of patients receiving nicorandil, but were generally minor in nature. There was not depressant effect on atrioventricular conduction, which occurs frequently in patients treated with calcium antagonists of the verapamil and diltiazem type. Nicrorandil may be effective even in patients with rest and effort angina who do not respond to combination therapy with calcium antagonists and oral nitrates. Thus, nicorandil appears to be a valuable addition to the arsenal of antianginal drugs due to its low incidence of serious side effects.
Similar content being viewed by others
References
Uchida Y, Yoshimoto N, Murao S. Effect of 2-nicotinamidethyl nitrate (SG-75) on coronary circulation.Jpn Heart J 1977;19:112–124.
Taira N, Satoh K, Yanagisawa T, et al. Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidoethyl nitrate (SG-75).Clin Exp Pharmacol Physiol 1979;6:301–316.
Sakai K, Shiraki Y, Nabata H. Cardiovascular effects of a new coronary vasodilator N-(2-hydroxyethyl) nicotinamide nitrate (SG-75): Comparison with nitroglycerin and diltiazem.J Cardiovasc Pharmacol 1981:3:139–150.
Satoh K, Yanagisawa T, Imai Y, et al. Cardiovascular actions of a new coronary vasodilator drugs, 2-nicotinamidethyl nitrate (SG-75) (in Japanese).Shinzo 1980;12:371–380.
Nakagawa Y, Takeda K, Katano Y, et al. Effects of 2-nicotinamidoethyl nitrate on the cardiovascular system.Jpn Heart J 1979;20:883–895.
Endoh M, Yanagisawa T, Taira N. Effects of 2-nicotinamidoethyl nitrate (SG-75), a new antianginal drug, on the cyclic AMP phosphodiesterase activity.Tohoku J Exp Ned 1980;130:139–201.
Neichi T, Tomisawa S, Kubodera N, et al. Enhancement of PGI2 formation by a new vasodilator 2-nicotinamidoethyl nitrate in the coupled system of platelets and aortic microsomes.Prostaglandins 1980;19:577–586.
Ogawa K, Enomoto I, Ito T, et al. SG-75 induction of increased coronary outflow and PGE1 from ischemic areas in dogs with experimental myocardial infarction.Jpn Heart J 1982;23:603–611.
Hardman HF, Pieper CM, Gross GJ. Lack of effect of cyclooxygenase blockade by indomethacin on the beneficial actions of nicorandil in the stunned myocardium of dogs (abstract). Tenth International Congress of Pharmacology, Sydney, 1987:639.
Holzmann S. Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75).J Cardiovasc Pharmacol 1983;5:364–370.
Kukovetz WR, Holzmann S. Mechanism of nitrate-induced vasodilation and tolerance.Z Kardiol 1983;72(Suppl 3):14–19.
Kukovetz WR, Holzmann S. Cyclic GMP in nicorandil-induced vasodilatation and tolerance development.J Cardiovasc Pharmacol 1987;10(Suppl 8):S25–S30.
Furukawa K, Itoh T, Kajiwara M, et al. Vasodilating actions of 2-nicotinamidoethyl nitrate on porcine and guineapig coronary arteries.J Pharmacol Exp Ther 1981;218: 248–259.
Itoh T, Furukawa K, Kaziwara M, et al. Effects of 2-nicotinamidoethyl nitrate on smooth muscle cells and on adrenergic transmission in the guinea-pig and porcine mesenteric arteries.J Pharmacol Exp Ther 1981;218:261–218.
Karashima T, Itoh T, Kuriyama H. Effects of 2-nicotinamidoethyl nitrate on smooth muscle cells of the guinea-pig mesenteric and portal veins.J Pharmacol Exp Ther 1981;221:472–480.
Allen SL, Foster RW, Morgan GP, et al. The relaxant action of nicorandil in guinea-pig isolated trachealis.Br J Pharmacol 1986;87:117–127.
Weir SE, Weston AH. The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on86Rb efflux in rat blood vessels.Br J Pharmacol 1986;88:121–128.
Yanagisawa T, Satoh K, Taira N. Circumstantial evidence for increased potassium conductance of membrane of cardiac muscle by 2-nicotinamideoethyl nitrate (SG-75).Jpn J Pharmacol 1979;29:687–694
Yanagisawa T, Taira N. Effect of 2-nicotinamidethyl nitrate (SG-75) on the membrane potential of left atrial muscle fibres of the dog.Naunyn-Schmiedeberg's Arch Pharmacol 1980;312:69–76.
Hester RK. Effects of 2-nicotinamidoethyl nitrate on agonist-sensitive Ca++ release and Ca++ entry in rabbit aorta.J Pharmacol Exp Ther 1985;233:100–111.
Murakami K, Karaki H, Urakawa N. Comparison of the inhibitory effects of nicorandil, nitroglycerin and isosorbide dinitrate on vasular smooth muscle of rabbit aorta.Eur J Pharmacol 1987;141:195–202.
Morimoto S, Koh E, Fukuo K, et al. Effect of nicorandil on the cytosolic free calcium concentration and microsomal (Ca2++Mg2+)-ATPase activity of vascular smooth muscle cells.J Cardiovasc Pharmacol 1987;10(Suppl 8):S31–S37.
Mizukami M, Tomoike H, Inouh T, et al. Effects of 2-nicotinamidethyl nitrate (SG-75) and/or nitroglycerin on the systemic hemodynamics and coronary blood flow in conscious dogs.Arzneim Forsch 1981;31:1244–1247.
Shiraki Y, Akima M, Nabata H, et al. The hypotensive mechanisms of the new anti-anginal drug, N-(2-hydroxyethyl)nicotinamide nitrate (SG-75) in beagle dogs.Jpn J Pharmacol 1981;31:921–929.
Sakanashi M, Noguchi K, Kato T, et al. Vasodilator effects of nicorandil and nitroglycerin in anesthetized open-chest dogs.Naunyn-Schmiedeberg's Arch Pharmacol 1986;333: 439–444.
Sakai K, Akima M, Shiraki Y, et al. Effects of a new antianginal agent, nicorandil, on the cardiovascular system of the miniature pig: With special reference to coronary vasospasm.J Pharmacol Exp Ther 1983;227:220–228.
Verdouw PD, Sassen LMA, Duncker DJ, et al., Nicorandil-induced changes in the distribution of cardiac output and coronary blood flow.Naunyn-Schmiedeberg's Arch Pharmacol 1987;336:352–358.
Kuromaru O, Sakai K. Comparison of development of tolerance between nicorandil and nitroglycerin in anesthetized, open-chest dogs.Jpn J Pharmacol 1986;42:199–208.
Kuromaru O, Sakai K. Cardiovascular effects of isosorbide dinitrate infused intravenously into anesthetized dogs.Clin Exp Pharmacol Physiol 1986;13:619–628.
Sakai K, Kuromaru O. Nitrate tolerance: Comparison of nicorandil, isosorbide dinitrate, and nitroglycerin in anesthetized dogs.J Cardiovasc Pharmacol 1987;10(Suppl 8):S17–S24.
Vatner SF, Massimo P, Rutherford RW, et al. Effects of nitroglycerin on cardiac function and regional blood flow distribution in conscious dogs.Am J Physiol 1978;234: H244-H.
Preuss KC, Gross GJ, Brooks HL, et al. Hemodynamic actions of nicorandil, a new antianginal agent, in the conscious dog.J Cardiovasc Pharmacol 1985;7:709–714.
Reeves T, Hefner LL, Jones WB, et al. The hemodynamic determinants of the rate of change in pressure in the left ventricle during isometric contractions.Am Heart J 1960;60:745–761.
Inoue K, Kuwaki K, Ueda K, et al. Evaluation of nicorandil as an antianginal drug (in Japanese).Igaku to Yakugaku 1982;7:229–243.
Habuchi Y, Nishimura M, Watanabe Y, et al. Electrophysiologic effects of nicorandil, a new antianginal agent, on action potentials and membrane currents of rabbit atrioventricular node.Naunyn-Schmiedeberg's Arch Pharmacol 1987:335:567–574.
Wada J, Endo M. Evaluation of antianginal drugs by coronary arteriography (in Japanese).Chiryo 1978;1:69–80.
Kurogane H, Hamamori Y, Hayashi T, et al. Clinical estimation of nicorandil(SG-75)—a hemodynamic study in comparison with nitroglycerin (in Japanese).Igaku to Yakugaku 1987;17:465–471.
Itoh H, Itoh H, Nakamura S, et al. Hemodynamic effect of SG-75 in patients with acute myocardial infarction (in Japanese).Rinsyoyakuri 1982;13:43–44.
Thormann J, Schlepper M, Kramer W, et al. Effectiveness of nicorandil (SG-75), a new long-acting drug with nitroglycerin effects in patients with coronary artery disease, improved left ventricular function and regional wall motion and abolition of pacing-induced angina.J Cardiovasc Pharmacol 1983;5:371–377.
Kambara H, Nakamura Y, Tamaki S, et al. Beneficial effects of nicorandil on cardiovascular hemodynamics and left ventricular function.J Cardiovasc Pharmacol 1987;10 (Suppl 8):S104–S108.
Ohnishi M, Maeda K, Fukuzaki W. Antianginal mechanism of nicorandil: Study on exercise invasive hemodynamics and thallium-201 myocardial perfusion images (in Japanese).J Jpn Coll Angiol 1987;27:191–195.
Kambara H, Tamaki S, Nakamura Y, et al. Effects of intravenous administration of nicorandil on cardiovascular hemodynamics and left ventricular function.Am J Cardiol 1989;63:56J-60J.
Yokota M, Horisawa T, Iwase M, et al. Effects of a new vasodilator, nicorandil, on exercise-induced impairment of left ventricular function in patients with old myocardial infarction.J Cardiovasc Pharmacol 1987;10(Suppl 8): S116–S122.
Solal AC, Jaeger P, Bouthier J, et al. Hemodynamic action of nicorandil in chronic congestive heart failure.Am J Cardiol 1989;63:44J-48J.
Silke B, Verma SP, Ali MS, et al. Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris.Am J Cardiol 1989;63:49J-55J.
Coltart DJ and Signy M. Acute hemodynamic effects of single-dose nicorandil in coronary artery disease.Am J Cardiol 1989;63:34J-39J.
Winbury MM, Howe BB, Hefner MA. Effect of nitrates and other coronary dilators on large and small coronary vessels: A hypothesis for the mechanism of action of nitrates.J Pharmacol Exp Ther 1969;168:70–95.
Brown G, Bolson E, Peterson RB, et al. The mechanism of nitroglycerin action: Stenosis vasodilation as a major component of drug response.Circulation 1981:64:1089–1097.
Hashimoto K, Ohbayashi Y, Yamaguchi S, et al. Effect of nicorandil on coronary and left ventricular hemodynamics in conscious dogs. In:Proceedings of the International Symposium on Cardiovascular Pharmacoloy, San Francisco, 1987:245.
Yamada A, Tomoike H, Hayashi Y, et al. Effects of nicorandil on large epicardial coronary artery in conscious dogs.Arzneim Forsch 1987;37:1252–1255.
Imai S, Nakazawa M, Takeda K, et al. Effects of nicorandil on the conductive coronary artery of the dog.J Cardiovasc Pharmacol 1987;10(Suppl 8):S10-S16.
Suryapranata K, Serruys PW, DeFeyter PJ, et al. Coronary vasodilatory action after a single dose of nicorandil.Am J Cardiol 1988;61:292–297.
Hata N, Kishida H, Kusama Y, et al. Coronary vasodilating actions and anti-anginal effects of nicorandil on coronary artery disease (in Japanese).J Jpn Coll Angiol 1987;27:1197–1201.
Aizawa T, Ogasahara K, Kato K. Effects of nicorandil on coronary ciruclation in patients with ischemic heart disease: Comparison with nitroglycerin.J Cardiovasc Pharmacol 1987;10(Suppl 8):S123–S129.
Kobayashi K, Yoshimura H, Kobayashi H, et al. Effect of nicorandil on coronary hemodynamics and cardiac metabolism in ischemic heart disease: Comparison with nitroglycerin, nifedipine and propranolol (in Japanese).Shinzo 1986:18:1153–1160.
Lamping KA, Warltier DC, Hardman HF, et al. Effects of nicorandil, a new antianginal agent, and nifedipine on collateral blood flow in a chronic coronary occlusion model.J Pharmacol Exp Ther 1984;229:359–363.
Lamping KA, Gross GJ, Comparative effects of a new nicotinamide nitrate derivative, nicorandil(SG-75), with nifedipine and nitroglycerin on true collateral blood flow following an acute coronary occlusion in dogs.J Cardiovasc Pharmacol 1984;6:601–608.
Uchida Y, Yoshimoto N, Murao S. Effect of 2-nicotinamidethyl nitrate (SG 75) on coronary circulation.Jpn Heart J 1977;19:112–124.
Epstein SE, Talbot TL. Dynamic coronary tone in precipitation, exacerbation and relief of angina pectoris.Am J Cardiol 1981;48:797–803.
Yasue H, Touyama M, Shimamoto M, et al. Role of autonomic nervous system in the pathogenesis of Prinzmetal's variant form of angina.Circulation 1974;50:534–539.
Yasue H, Omoto S, Takizawa A, et al. Pathogenesis and treatment of angina pectoris at rest as seen from its response to various drugs.Jpn Circ J 1978;42:1–10.
Sakai K, Akima M, Tsuyama K. Evaluation of the isolated perfused heart of mice, with special reference to vasoconstriction caused by intracoronary acetylcholine.J Pharmacol Methods 1983;10:263–270.
Sakai K. Coronary vasoconstriction by locally administered acetylcholine, carbachol and bethanechol in isolated, donorperfused, rat hearts.Br J Pharmacol 1980;68:625–632.
Sakai K, Akima M, Adachi J. Pharmacological features of the coronary, renal, mesenteric, and femoral vascular bed of rats revealed by intra-arterial administration of drugs.J Cardiovasc Pharmacol 1980;453–470.
Sakai K. Vasoconstriction produced by intracoronary cholinomimetic drugs in isolated donor-perfused hearts of rhesus monkeys: Comparison with pig, dog, and rabbit hearts.J Cardiovasc Pharmacol 1981;3:500–509.
Satoh K, Maruyama M, Yamashita S, et al. Nicorandil releases acetylcholine-induced sustained coronary arterial constriction in monkeys and baboons.Jpn Heart J 1984;25:267–273.
Yasue H, Horio Y, Nakamura N, et al. Induction of coronary spasm by acetylcholine in patients with variant angina: Possible role of the parasympathetic nerve system in the pathogenesis of coronary artery spasm.Circulation 1986;74:955–963.
Okumura K, Yasue H, Matsuyama K, et al. Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm.J Am Coll Cardiol 1988;12:883–888.
Aono J, Akima M, Sakai K. Effects of N-(2-hydroxyethyl) nicotinamide nitrate (SG-75) on methacholine-induced ECG changes in intact anesthetized rats.Jpn J Pharmacol 1981;31:823–830.
Leitold M, Hader S. Einfluß antianginöser Substanzen auf die durch Lypressin induzierte T-Wellenerhöhung im EKG der Ratte.Arzneim Forsch 1986;36:1454–1457.
Lamping KA, Christensen CW, Pelc LR, et al. Effects of nicorandil and nifedepine on protection of ischemic myocardium.J Cardiovasc Pharmacol 1984;6:536–542.
Lamping KG, Gross GJ. Improved recovery of myocardial segment function following a short coronary occlusion in dogs by nicorandil, a potential new antianginal agent, and nifedipine.J Cardiovasc Pharmacol 1985;7:158–166.
Gross GJ, Wartier DC, Hardman HF. Comparative effects of nicorandil, a nicotinamide nitrate derivative, and nifedipine on myocardial reperfusion injury in dogs.J Cardiovasc Pharmacol 1987;10:535–542.
Gross GJ, Pieper GM, Warltier DC. Comparative effects of nicorandil, nitroglycerin, nicotinic acid, and SG-86 on the metabolic status and functional recovery of the ischemicreperfused myocardium.J Cardiovasc Pharmacol 1987;10 (Suppl 8):S76–S84.
Abiko Y, Ichihara K, Sakai K. Effects of nicorandil and other antianginal drugs on myocardial pH in the ischemic dog heart.J Cardiovasc Pharmacol 1987;10(Suppl 8):S85–S91.
Nakamura Y, Kojima S, Mori H, et al. Examination of the direct effects of nicorandil, verapamil, propranolol, and nitroglycerin on the hypoxic canine myocardium.J Cardiovasc Pharmacol 1987;10(Suppl 8):S92-S97.
Pieper GM, Gross GJ. Salutory action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: Comparison with isosorbide dinitrate.Circulation 1987;76:916–928.
Endo T, Nejima J, Kiuchi K, et al. Reduction of size of myocardial infarction with nicorandil, a new antianginal drug, after coronary artery occlusion in dogs.J Cardiovasc Pharmacol 1988;12:587–592.
Korb H, Hoeft A, Hunneman PH, et al. Effectiveness of nicorandil in the preservation of myocardium stressed by transient ischemia and its influence on cardiac metabolism during coronary artery occlusion with subsequent reperfusion: A comparison with isosorbide dinitrate.Naunyn-Schmiedeberg's Arch Pharmacol 1985;329:440–446.
Stewart DD. Remarkable tolerance to nitroglycerin.Philadelphia Polyclinic, 1888, p. 172;JAMA 1905;44:1678–1679.
Packer M, Lewe WH, Kessler PDF, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure.N Engl J Med 1987;317:799–804.
Parker JO, Farrell B, Lahey KA, et al. Nitrate tolerance: The lack of effect of N-acetylcysteine.Circulation 1987;76:572–576.
Elkayam U, Kulick D, McIntosh N, et al. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure.Circulation 1987:76:577–584.
Nabata H, Shiraki Y, Sakai K. Development of tolerance and a new coronary vasodilator, N-(2-hydroxyethyl) nicotinamide nitrate (SG-75): A comparison with nitroglycerin.Jpn J Pharmacol 1981;31:511–519.
Tsutamoto T, Kanamori T, Mitsunami K, et al. Nicorandil does not develop tolerance in patients with congestive heart failure.Circulation 1989;80:II215.
Ishizaki T, Chiba K, Suganuma T, et al. Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs.J Pharm Sci 1984;73:494–498.
Hinohara Y, Tohira Y, Kamiyama H, et al. Metabolism of N-(2-hydroxyethyl) nicotinamide nitrate (SG-75) (1): Absorption, distribution, excretion, transplacental distribution and transfer to milk following oral administration of14C-SG-75 to rats (in Japanese).Appl Pharmacol 1982;23:153–163.
Frydman AM, Chapelle P, Diekmann H, et al. Pharmacokinetics of nicorandil.Am J Cardiol 1989;63:25J-33J.
Noda S, Tsuzuki S, Shiki K, et al. Antianginal effect and its duration of nicorandil, estimated by treadmill exercise tests (in Japanese).Rinsyouyakuri 1982;13:129–259.
Nakatani H, Kanda K, Oyama Y, et al. Effect of SG-75 (2-nicotinamidethyl nitrate) on pharmacokinetics and systemic hemodynamics (in Japanese).Rinsyoyakuri 1979; 10:116–117.
Kinoshita H, Kumaki K, Suzuki H, et al. Metabolism of N-(2-hydroxyethyl) nicotinamide nitrate (ester) (SG-75) (3) Metabolism of14C-SG-75 in rats, guinea pigs and dog (in Japanese).Appl Pharmacol 1982;23:253–259.
Kinoshita M, Nishikawa S, Sawamura M, et al. Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris.Am J Cardiol 1986;58:733–738.
Murao S, Kimura E, Harumi K, et al. Clinical investigation of SG-75 on angina pectoris. Multicenter study of early phase II (in Japanese).Rinsyo to Kenkyu 1981;58:1908–1922.
Yamashita H, Tosaka S, Haneda S, et al. Clinical experimence with nicorandil(SG-75) on angina pectoris (in Japanese).Yakuri to Chiryou 1982;10:845–857.
Endoh S, Kotake H, Aume M, et al. The efficacy of nicorandil in patients with angina pectoris (in Japanese).Saishin Igaku 1982;37:2175–2180.
Hamada K, Matsuzaki K, Ochi T, et al. Clinical studies on the efficacy of nicorandil (N-(2-hydroxyethyl) nicotinamide nitrate) (in Japanese).Rinsyo to Kenkyu 1982;59:2399–2408.
Fujinaga A, Nishijima S, Toyoda S, et al. Clinical experimence of nicorandil on angina pectoris (in Japanese).Shinyaku to Rinsyo 1982;31:167–170.
Hirazawa K, Yokota H, Tateda K, et al. Clinical experience of nicorandil (SG-75) on angina pectoris (in Japanese).Shinyaku to Rinsyo 1981;30:1741–1748.
Wakabayashi O. Clinical experience of nicorandil on angina pectoris (in Japanese).Shinryou to Shinyaku 1982;19:311–317.
Oyama Y. Effect of SG-75 on angina pectoris (in Japanese).Drug Therapy 1980;13:563–570.
Morita K. Clinical experience of nicorandil on angina pectoris (in Japanese).Shinryou to Shinyaku 1981;18:2577–2583.
Ide M, Tanabe A, Gotou Y. Clinical experience of nicorandil (SG-75) on angina pectoris (in Japanese).Shinyaku to Chiryou 1982;19:319–323.
Tanaka H, Hayashi T, Obara M et al. Clinical experience of SG-75 (nicorandil) on angina pectoris (in Japanese).Yakuri to Chiryou 1982;10:5443–5449.
Arakawa K, Fujino M, Abe K, et al. Clinical experience of nicorandil(SG-75) on angina pectoris (in Japanese).Rinsyo to Kenkyu 1982;59:1287–1295.
Kinoshita S, Hayashi Y, Sasaki H et al. Clinical studies on the efficacy of a new antianginal drug, SG-75 (in Japanese).Rinsyo to Kenkyu 1981;58:3429–3437.
Satoh K, Takizawa I, Hirano K, et al. Clinical experience of nicorandil(SG-75) on angina pectoris (in Japanese).Shinyaku to Rinsyo 1981;30:1987–1993.
Odazima H, Ogata K, Terasawa Y, et al. Dose-response estimation of nicorandil (SG-75) in patients with angina pectoris (in Japanese).Yakuri to Chiryou 1982;10:831–857.
Mizuno Y, Hishida J, Okajima T, et al. Clinical experience of nicorandil on ischemic heart disease (in Japanese).Shinyaku to Rinsyo 1982;31:37–43.
Takishima H, Inooka E. Clinical study on nicorandil in patients with angina pectoris (in Japanese).Rinsyo to Kenkyu 1986;63:1001–1011.
Murao S, Kimura E. Clinical effect of nicorandil on angina pectoris. A double blind trial in comparison with propranolol (in Japanese).Clin Pharmacol 1982;13:311–326.
Yamada K, Takezawa H, Toyoma S, et al. Clinical studies on the efficacy of SG-75(nicorandil) in patients with angina pectoris. Double blind comparison with nifedipine (in Japanese).Rinsyo to Kenkyu 1982;59:2079–2089.
Kurogane H, Nanzi K, Hamamori Y, et al. Clinical study on the efficacy of an antianginal drug, nicorandil (SG-75). A randomised, crossover study with nifedipine.Igaku to Yakugaku 1987;17:721–730.
Mimura G, Irei M, Kinjo K, et al. Studies on clinical evaluation of nicorandil(SG-75) on angina pectoris. Comparison with the sustained release tablet of isosorbide dinitrate (in Japanese).Yakuri to Chiryou 1985;13:4203–4216.
Belz GG, Matthews J, Heinrich J, et al. Controlled comparison of the pharmacodynamic effects of nicorandil(SG-75) and isosorbide dinitrate in man.Eur J Clin Pharmacol 1984;26:681–685.
Belz GG, Matthews JH, Beck A, et al. Hemodynamic effects of nicorandil, isosorbide dinitrate and dihydralazine in healthy volunteers.J Cardiovasc Pharmacol 1985;7:1107–1112.
Redwood DR, Rosing DR, Goldstein RE, et al. Improtance of the design of an exercise protocol in the evaluation of patients with angina pectoris.Circulation 1971;43:618–628.
Hayata N, Araki H, Nakamura M. Effects of nicorandil on exercise tolerance in patients with stable effort angina: A double-blind study.Am Heart J 1986;112:1245–1250.
Furukawa K, Kitamura H, Kohda M, et al. Effect of nicorandil on exercise capacity in patients with chronic exertional angina (in Japanese).Shinzo 1985;17:27–32.
Kato K, Asanoi H, Wakabayashi C, et al. Effect of nicorandil on exercise performance in patients with effort angina: A multicenter trial using a treadmill exercise test.J Cardiovasc Pharmacol 1987;10(Suppl 8):S98–S103.
Hiasa Y, Morimoto S, Maeda T, et al. Effect of nicorandil (Sigmart) on exercise tolerance in patients with stable exercise angina pectoris (in Japanese).Rinsyo to Kenkyu 1986;63:1745–1749.
Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris.Am J Cardiol 1989;63:61J-65J.
Meany TB, Richardson P, Camm J, et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris.Am J Cardiol 1989;63:66J-70J.
Kishida H, Murao S. Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris.Clin Pharmacol Ther 1987;42:166–174.
Kawai C, Kambara H, Kaburagi T, et al. Effect of nicorandil on patients with rest angina pectoris with special reference to its clinical effect and blood concentration (in Japanese).Yakuri to Chiryou 1986;13:3421–3433.
Araki H, Hayata N, Matsuguchi T, et al. Effects of nicorandil on rest and effort angina unresponsive to combination therapy with a calcium antagonist and oral nitrate.Clin Ther 1987;9:174–182.
Ishikawa T, Imamura T, Kiowaya Y, et al. Atrioventricular dissociation and sinus arrest induced by oral diltiazem.N Engl J Med 1983;309:1124–1125.
Hinohara Y, Yamazaki T, Kuromaru O, et al. Effects of nicorandil and verapamil, antianginal agents, on plasma digoxin concentrations in rats and dogs.J Pharm Pharmacol 1987;39:512–516.
Signy M, Crowther A, Coltart DJ. The effect of sublingual nicorandil on central and peripheral hemodynamics (abstract): In:Proceedings of the International Symposium on Cardiovascular Pharmacology, Geneva, 1985:256.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kinoshita, M., Sakai, K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drug Ther 4, 1075–1088 (1990). https://doi.org/10.1007/BF01856503
Issue Date:
DOI: https://doi.org/10.1007/BF01856503